

Maryam Daneshpazhoob, MD,<sup>a</sup> Hamidreza Mahmoudi, MD,<sup>a</sup> Kamran Balighi, MD,<sup>a</sup> Amir Teimourpour, PhD,<sup>a,b</sup> Zobreh Khodasbenas, MD,<sup>a</sup> Maryam Gbiasi, MD,<sup>a</sup> Hasan Khosravi, MD,<sup>a,c</sup> and Cheyda Chams-Davatchi, MD<sup>a</sup>

From the Autoimmune Bullous Diseases Research Center, Department of Dermatology, Tebran University of Medical Sciences, Tebran, Iran<sup>a</sup>; Department of Epidemiology and Biostatistics, School of Public Health, Tebran University of Medical Sciences, Tebran, Iran<sup>b</sup>; and Mount Auburn Hospital, Cambridge, Massachusetts<sup>c</sup>

Drs Daneshpazhoob and Mahmoudi contributed to this work equally.

Funding sources: Supported by a grant from Tebran University of Medical Sciences (94-02-101-29411).

Conflicts of interest: None disclosed.

Previously presented: Presented as a poster at the International Pemphigus and Pemphigoid Foundation scientific conference in Lübeck, Germany, June 21-23, 2017.

Reprints not available from the authors.

Correspondence to: Maryam Daneshpazhoob, MD, Autoimmune Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Vahdate-Eslami Square, Tebran, Iran 11996

E-mail: [daneshpj@tums.ac.ir](mailto:daneshpj@tums.ac.ir), [maryamdanesb.pj@gmail.com](mailto:maryamdanesb.pj@gmail.com)

## REFERENCES

1. Kamiya K, Aoyama Y, Shirafuji Y, et al. A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris. *J Dermatol Sci*. 2013;70:190-195.
2. Li Z, Zhang J, Xu H, Jin P, Feng S, Wang B. Correlation of conventional and conformational anti-desmoglein antibodies with phenotypes and disease activities in patients with pemphigus vulgaris. *Acta Derm Venereol*. 2015;95:462-465.
3. Nakahara T, Takagi A, Yamagami J, et al. High anti-desmoglein 3 antibody ELISA index and negative indirect immunofluorescence result in a patient with pemphigus vulgaris in remission: evaluation of the antibody profile by newly developed methods. *JAMA Dermatol*. 2014;150:1327-1330.
4. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *J Am Acad Dermatol*. 2008;58:1043-1046.
5. Daneshpazhoob M, Zafarmand Sedigh V, Balighi K, et al. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission. *J Am Acad Dermatol*. 2016;74:1160-1165.
6. Albers LN, Liu Y, Bo N, Swerlick RA, Feldman RJ. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. *J Am Acad Dermatol*. 2017. <https://doi.org/10.1016/j.jaad.2017.07.012> [Epub ahead of print].

<https://doi.org/10.1016/j.jaad.2018.03.035>

## Adverse reactions to tattoos in the general population of Denmark



*To the Editor:* The prevalence of permanent tattooing is increasing,<sup>1,2</sup> along with its harms. Case studies provide mounting evidence of various tattoo-associated skin problems often ascribed to red and black ink.<sup>3</sup> However, as the prevalence of tattoo-related skin reactions in the general population is unknown, the scale of the adverse reactions remains uncertain. Tattooing has been associated with marginalized societal groups,<sup>4</sup> but little is known about the current social characteristics of the tattooed population.

Our baseline cohort study from 2006 comprised 3471 randomly selected adult Danes representative of the general population. Five years later, a follow-up was conducted including 2212 individuals (participation rate 63.7%) who answered questions regarding permanent tattoos, adverse skin reactions, and social characteristics. Permanent tattooing was defined as a tattoo pricked into the skin by a needle. We used SPSS version 22 for descriptive statistics and regression models to estimate odds ratios (ORs) with 95% confidence intervals (95% CIs).

In total, 14.2% had  $\geq 1$  tattoo (Table I). Tattoos were more frequent among the young age groups, with 28.6% for those 24-30 years of age and 27.1% for those 31-39 years of age compared with 10.4% in the 40-76 year age group. More men were tattooed than women, and men were younger (median age 20 years) than women (median age 28 years) when they had their first tattoo ( $P < .001$ ). Notably, tattooed individuals were more often unmarried, less educated, and cohabiting than individuals without tattoos. Moreover, they had an unhealthy diet, frequently used tanning beds, and rated their social position as in the middle (Table I).

Adverse reactions to tattoos were reported by 5.9% (18 of 306). The reasons for adverse reactions were eczema/rash (2.9%), infection (1.3%), erosions (1.0%), or all symptoms (0.7%). In most cases, the adverse reactions disappeared without any action; 5.6% of reactions disappeared after medical treatment and 11.1% of individuals had the tattoo removed (Table II). Red ink was involved in most adverse reactions.

**Table I.** Characteristics of study population from Health2006 cohort and logistic regression analysis with  $\geq 1$  tattoo as dependent variable and covariates influencing likelihood of having tattoo as independent variables

Explanatory variables	No tattoos, % (n)	$\geq 1$ tattoo, % (n)	P value, $\chi^2$ test	OR (95% CI)
<b>General</b>				
All participants, n = 2212	85.8 (1899)	14.2 (313)		
<b>Sex</b>				
Female, n = 1190	89.0 (1059)	11.0 (131)	<.001	Reference
Male, n = 1022	82.2 (840)	17.8 (182)		<b>1.89 (1.48-2.43)*</b>
<b>Age group, y</b>				
40-76	89.6 (1546)	10.4 (180)	<.001	Reference $\phi$
31-39	72.9 (283)	27.1 (105)		<b>3.34 (2.53-4.40)<sup>†</sup></b>
24-30	71.4 (70)	28.6 (28)		<b>3.65 (2.28-5.84)<sup>†</sup></b>
<b>Skin health</b>				
Itchy skin ever	48.3 (897/1856)	46.5 (140/301)	.558	1.05 (0.81-1.34)
Itchy skin within past 12 months	56.9 (645/1133)	54.9 (100/182)	.616	1.08 (0.78-1.49)
<b>Social characteristics and lifestyle</b>				
<b>Marriage, n = 2204</b>				
Ever married	85.6 (1619/1892)	70.5 (220/312)	<.001	Reference
Unmarried	14.4 (273/1892)	29.5 (92/312)		<b>1.80 (1.30-2.48)</b>
<b>Cohabitation, n = 2162</b>				
Never cohabited	42.2 (783/1856)	27.1 (83/306)	<.001	Reference
Ever cohabited	57.8 (1073/1856)	72.9 (223/306)		<b>1.74 (1.32-2.29)</b>
<b>Educational level, n = 2132</b>				
High	59.0 (1082/1833)	37.5 (112/299)	<.001	Reference
Low, <7-10 y	41.0 (751/1833)	62.5 (187/299)		<b>2.92 (2.23-3.84)</b>
<b>Social position, self-assessed, n = 2198</b>				
High	32.9 (620/1886)	24.7 (77/312)	<.05	Reference
Middle	64.8 (1222/1886)	72.8 (227/312)		<b>1.74 (1.30-2.32)</b>
Low	2.3 (44/1886)	2.6 (8/312)		1.51 (0.67-3.40)
<b>Diet, self-assessed, n = 2196</b>				
Healthy	27.0 (508/1884)	20.5 (64/312)	<.05	Reference
Average	64.9 (1222/1884)	66 (206/312)		1.20 (0.88-1.63)
Unhealthy	8.2 (154/1884)	13.5 (42/312)		<b>1.83 (1.17-2.86)</b>
<b>Tanning habits</b>				
Use of sunscreen during summer	63.4 (1194/1882)	65.4 (202/309)	.513	0.90 (0.68-1.18)
Use of tanning bed	8.7 (164/1889)	26.9 (84/312)	<.001	<b>3.89 (2.84-5.34)</b>

Bold indicates statistically significant by logistic regression analysis ( $P < .05$ ).

CI, Confidence interval; OR, odds ratio.

\*Adjusted for age.

<sup>†</sup>Adjusted for sex.

Our study suggests that tattooing is becoming more mainstream, which is in-line with previous literature.<sup>2</sup> We show that 5.9% of tattooed individuals report adverse reactions, which is high considering our focus on well-defined clinical symptoms. Potentially this restricted range of reactions from our questionnaire was a study limitation, resulting in an underestimation of the prevalence of tattoo-associated problems. Further, we do not know when the reactions occurred, and whether they were late events or associated with the pricking itself. A low rate of medical consultation and a habit of consulting the tattooist or asking tattooed friends for advice regarding

tattoo-related skin problems have been shown elsewhere.<sup>5</sup> However, the tattooist is not required to report adverse reactions or to provide general risk information. Face-to-face interviews in tattooed subgroups have shown that 42% of 144 tattooed sunbathers in Denmark experienced complaints<sup>5</sup> and 10.3% of 300 tattooed individuals in Central Park, New York, had experienced an adverse reaction.<sup>3</sup> The high number of adverse reactions supports the need for systematic surveillance regarding tattoo-related skin problems. Our findings underline the importance of counseling emphasizing risks associated with red ink.

**Table II.** Self-reported adverse skin reactions in tattooed population (N = 306)

Adverse skin reaction in tattoo and characteristics	Value, n (%)
Adverse skin reaction in tattoo, self-reported	18 (5.9)
Eczema/rash	9 (2.9)
Infection	4 (1.3)
Erosion	3 (1.0)
All 3	2 (0.7)
Sex, male	9 (50)
Age group, y	
24-30, n = 28	1 (3.6)
31-39, n = 105	6 (5.7)
40-76, n = 180	11 (6.1)
Low educational level (<7-10 years), n = 187	10 (5.3)
Skin health	
Itchy skin ever, n = 140	12 (8.6)
Itchy skin within the past 12 months, n = 100	8 (8.0)
Tanning habits	
Use of sunscreen, n = 202	12 (5.9)
Use of tanning bed, n = 84	4 (4.8)
Color affected by adverse reaction ( <i>P</i> value = .22, Fisher's exact test)	
Blue	1
Black	4
Red	4
Green	0
Yellow	2
Mix*	5
Other	1
No answer	1
Handling of adverse reaction ( <i>P</i> = .239, Fisher's exact test)	
Disappeared without any action	12
Disappeared after medical treatment	1
Tattoo had to be removed	2
Other	2
No answer	1

\*Blue and red; red, green, yellow, and other; yellow and other; blue, red, green, and yellow; and black, red, green, and yellow.

Rie Dybboe Bjerre, MSc,<sup>a</sup> Nina Heede Ulrich, PhD,<sup>a</sup> Allan Linneberg, MD,<sup>b,c,d</sup> and Jeanne Duus Jobansen, MD<sup>a</sup>

From the Department of Dermatology and Allergy, National Allergy Research Centre, Herlev-Gentofte Hospital, University of Copenhagen, Denmark<sup>a</sup>; Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark<sup>b</sup>; Research Centre for Prevention and Health, Capital Region, Copenhagen, Denmark<sup>c</sup>; and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark<sup>d</sup>

*Funding sources:* Supported by the Tryg Foundation (7-11-0213) and an unrestricted grant from the Danish Environmental Protection Agency.

*Conflicts of interest:* None disclosed.

*Correspondence to:* Rie Dybboe Bjerre, MSc, Department of Dermatology and Allergy, National Allergy Research Centre, Herlev-Gentofte Hospital, Kildegaardsvej 28, 2900 Hellerup, Denmark

*E-mail:* [rie.dybboe.bjerre@regionh.dk](mailto:rie.dybboe.bjerre@regionh.dk)

#### REFERENCES

1. Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. *J Am Acad Dermatol.* 2006;55(3):413-421.
2. Sagoe D, Pallesen S, Andreassen CS. Prevalence and correlates of tattooing in Norway: a large-scale cross-sectional study. *Scand J Psychol.* 2017;58(6):562-570.
3. Brady BG, Gold H, Leger EA, Leger MC. Self-reported adverse tattoo reactions: a New York City Central Park study. *Contact Dermatitis.* 2015;73(2):91-99.
4. Pers M, von Herbst T. The demand for removal of tattoos. A plea for regulations against tattooing of minors. *Acta Chir Scand.* 1966;131(3):201-204.
5. Hutton Carlsen K, Serup J. Photosensitivity and photodynamic events in black, red, and blue tattoos are common: a 'beach study'. *J Eur Acad Dermatol Venereol.* 2014;28(2):231-237.

<https://doi.org/10.1016/j.jaad.2018.03.038>

#### Management of primary cutaneous CD4<sup>+</sup> small and medium pleomorphic T-cell lymphoma: A retrospective study



*To the Editor:* Primary cutaneous small and medium CD4<sup>+</sup>T-cell lymphoma (CD4<sup>+</sup> PCSM-TCL) is a rare variant of T-cell lymphoproliferative disorder accounting for 2% of all primary cutaneous lymphomas.<sup>1</sup> Clinically, this lymphoma is generally indolent and presents as a solitary papule, plaque, or nodule predominantly on the face, neck, or upper trunk.<sup>1</sup> On histologic analysis, it is characterized by a dense, nodular or diffuse lymphocytic infiltrate in the dermis. In the 2016 World Health Organization (WHO) classification, CD4<sup>+</sup> PCSM-TCL is categorized as a primary cutaneous small- or medium-sized T-cell lymphoproliferative disorder given its indolent behavior and favorable outcomes.<sup>2</sup> However, no standard of care was established due to its rarity.

We retrospectively reviewed a cohort of 684 patients with a diagnosis of cutaneous lymphoma during 2008-2015 under an institutional review board-approved protocol. By using the 2005 WHO and European Organisation for Research